GILEAD SCIENCES, INC. GILD

Latest FY: 2025 Healthcare Drug Manufacturers - General
Market Price $138.36
Market Cap $171.42B
P/E Ratio 20.41
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑2.4% YoY
$29.44B
3-Yr CAGR: 2.6%
Net Income ↑1,672.9% YoY
$8.51B
Net Margin: 28.9%
Free Cash Flow ↓-8.2% YoY
$9.46B
FCF Yield: 5.52%
EPS (Diluted) ↑1,684.2% YoY
$6.78
Basic: $6.84
Return on Equity Efficiency
37.5%
ROA: 14.4%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (GILD)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $30,390.0M $26,129.0M $13,501.0M $9.94 $16,669.0M $15,921.0M
FY 2017 $26,107.0M -14.1% $21,736.0M $4,628.0M -65.7% $3.51 -64.7% $11,898.0M $11,308.0M -29.0%
FY 2018 $22,127.0M -15.2% $17,274.0M $5,455.0M +17.9% $4.17 +18.8% $8,400.0M $7,476.0M -33.9%
FY 2019 $22,449.0M +1.5% $17,774.0M $5,386.0M -1.3% $4.22 +1.2% $9,144.0M $8,319.0M +11.3%
FY 2020 $24,689.0M +10.0% $20,117.0M $123.0M -97.7% $0.10 -97.6% $8,168.0M $7,518.0M -9.6%
FY 2021 $27,305.0M +10.6% $20,704.0M $6,225.0M +4,961.0% $4.93 +4,830.0% $11,384.0M $10,805.0M +43.7%
FY 2022 $27,281.0M -0.1% $21,624.0M $4,592.0M -26.2% $3.64 -26.2% $9,072.0M $8,344.0M -22.8%
FY 2023 $27,116.0M -0.6% $20,618.0M $5,665.0M +23.4% $4.50 +23.6% $8,006.0M $7,421.0M -11.1%
FY 2024 $28,754.0M +6.0% $22,503.0M $480.0M -91.5% $0.38 -91.6% $10,828.0M $10,305.0M +38.9%
FY 2025 $29,443.0M +2.4% $23,209.0M $8,510.0M +1,672.9% $6.78 +1,684.2% $10,019.0M $9,456.0M -8.2%
$

Valuation

Market Price $138.36
Market Cap $171.42B
Enterprise Value $188.80B
P/E Ratio 20.41
P/B Ratio 7.57
FCF Yield 5.52%
Dividend Yield 2.28%
Shares Outstanding 1,241,569,900
%

Profitability & Margins

Gross Margin 78.83%
Operating Margin 34.04%
Net Margin 28.90%
Return on Equity (ROE) 37.48%
Return on Assets (ROA) 14.42%
Asset Turnover 0.50x
Revenue 3-Yr CAGR 2.57%
🛡️

Financial Health & Liquidity

Current Ratio 0.34
Cash Ratio 0.64
Debt / Equity 1.098
Debt / Assets 0.422
Cash & Equivalents $7.56B
Total Debt $24.94B
Book Value / Share $18.29
💧

Cash Flow Efficiency

Operating Cash Flow $10.02B
Capital Expenditures (CapEx) $563.00M
Free Cash Flow $9.46B
OCF / Revenue 34.03%
FCF / Revenue 32.12%
FCF 3-Yr CAGR 4.26%
🏷️

Per Share Metrics

EPS (Diluted) $6.78
EPS (Basic) $6.84
Dividends / Share $3.16
Book Value / Share $18.29
EPS YoY Growth 1,684.21%
🏛️

Balance Sheet (FY 2025)

Total Assets $59.02B
Total Liabilities $59.02B
Stockholders' Equity $22.70B
Current Assets $4.02B
Current Liabilities $11.81B